Previous 10 | Next 10 |
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics ...
PRESS RELEASE Boston , MA U.S.A. ( December 1 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® ...
Allarity Therapeutics press release ( NASDAQ: ALLR ): Q3 Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021. For further details see: Allarity Therapeutics reports Q3 results
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion ...
Press release Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagno...
(NewsDirect) Once brought into its pipeline , Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year, the company refocused its pipeline strategy toward co...
--News Direct-- Once brought into its pipeline , Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year, the company refocused its pipeline strategy toward...
Allarity Therapeutics press release ( NASDAQ: ALLR ): Q2 GAAP EPS of -$0.72 misses by $0.46 . As of June 30, 2022, Allarity’s cash was $7.7 million, as compared to $19.6 million as of December 31, 2021 Shares +4.07% . For further details see: A...
Cambridge, MA U.S.A. ( October 11 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagn...
Press release Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
7.99%Change Percent:
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the ...
Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity The...